Election Results 2026 MidtermsView →
Dock Line
The John Mendelsohn Faculty Center and T. Boone Pickens Academic Tower on the UT MD Anderson Cancer Center campus in Houston, photographed in February 2024 under a cloudy sky
The John Mendelsohn Faculty Center and T. Boone Pickens Academic Tower on the UT MD Anderson Cancer Center campus in Houston, photographed in February 2024. A Nov. 12 Science paper and MD Anderson release describe an atlas of cells surrounding early, preinvasive breast cancers. (Kenneth C. Zirkel / Wikimedia Commons)

Jane Long

November 16, 2026 · 4 min read

MD Anderson Maps the Cells Surrounding Early Breast Cancers

A Nov. 12 Science paper and MD Anderson release describe an atlas of 854,911 cells from 159 patients around estrogen-receptor-positive DCIS, the most common form of stage 0 breast cancer. The institution says more research is needed before the work can guide treatment.

Researchers at The University of Texas MD Anderson Cancer Center have built what a Nov. 12 news release calls "one of the most detailed maps to date" of the cells surrounding ductal carcinoma in situ, or DCIS, which the Houston institution describes as the most common form of preinvasive, or stage 0, breast cancer. The findings, the release says, "may help explain why some lesions progress to invasive breast cancer and others do not," and could inform later efforts to improve risk prediction and target care for patients at higher risk of invasive disease. The study was published the same day in the journal Science as "A cellular atlas of the preinvasive breast cancer microenvironment," by Siyuan He, Aatish Thennavan, and colleagues (DOI: 10.1126/science.aef4622). This report is based on the MD Anderson release and the paper's abstract. The full article is not open access and was not read in full.

The release lists the study as co-led by Nicholas Navin, Ph.D., chair of Systems Biology at MD Anderson; Savitri Krishnamurthy, M.D., professor of Anatomical Pathology at MD Anderson; and Alastair Thompson, M.D., a surgical oncologist at Baylor College of Medicine, with co-first authors Siyuan He, Ph.D., and Aatish Thennavan, Ph.D., postdoctoral fellows of Systems Biology at MD Anderson. Those names and affiliations match the paper's author list, which also includes other MD Anderson and Baylor co-authors.

According to the release, DCIS occurs when abnormal cells grow inside the breast milk ducts but have not yet spread into surrounding tissue, and it is considered a precursor to the most common type of breast cancer. The release says mammograms and other breast examinations have increased the detection of DCIS, but that "many of these lesions never progress to invasive disease, making it challenging to determine which patients actually need more aggressive treatment." A summary line in the release also states that "not all cases will progress and many patients undergo unnecessary treatments." Those statements are the institution's account in the release; this report does not add incidence figures, progression rates, or a list of treatments.

"DCIS is considered a snapshot before breast cancer becomes invasive, but not all DCIS cases progress to invasive disease, and the biology surrounding these lesions has been challenging to examine," Navin said in the release. "This atlas reveals the surrounding cells and structures that may help disease become invasive. In the future, these findings may allow clinicians to better identify and treat patients with DCIS who are at higher risk of invasive progression while also avoiding unnecessary treatments for those at low risk."

The paper's abstract is more specific than the release about the study's scope and counts. It says the researchers "constructed a comprehensive atlas of the TME in estrogen-receptor positive DCIS using fresh samples collected from normal breast tissues, DCIS and invasive breast cancers," and that they "analyzed 854,911 cells from 159 patients by single cell RNA sequencing and 39 samples by spatial transcriptomics, which identified 9 cell types and 60 cell states." The release rounds that cell count to "more than 850,000 cells" and does not state the patient or sample numbers, the nine cell types and 60 cell states, or that the atlas is of estrogen-receptor-positive DCIS. The abstract reports "remodeling of fibroblasts, vascular and basal cells that encircle the DCIS regions and immunosuppressive ducts that support the growth of the preinvasive cancer cells," and says the study "delineates early alterations in the DCIS TME, including many changes that persist during invasive progression." The release separately says the study uncovered previously unknown "cancer stromal loops," which it describes as "ring-like structures made of supportive tissue and vascular cells that surround DCIS lesions, which create conditions that support tumor growth." That phrase does not appear in the abstract. The release also says the atlas "suggests that important biological changes associated with invasive breast cancer begin to emerge earlier than previously known," which goes further than the abstract's wording and is kept here as the institution's account.

The release is careful about what the work does not yet do. "Additional research is needed to validate these findings and evaluate their potential use in future diagnostic tools and prevention or treatment strategies," it says. Researchers "will continue studying the cellular features identified in this atlas to determine whether they can predict which DCIS lesions are most likely to become invasive in order to better determine the best strategies for individual patients." The abstract does not say the atlas is ready for clinical use, and it does not claim that doctors can already tell which patients may safely skip treatment.

The work was supported in part by the National Cancer Institute, the Cancer Prevention and Research Institute of Texas, the Vivian L. Smith Foundation, and UT MD Anderson institutional funding, the release says. It directs readers to the Science paper for a full list of collaborating authors, disclosures, and funding sources. Those details are not restated here. Dock Line recently reported on MD Anderson's $3.4 billion plan to expand its Texas Medical Center campus; that earlier story is about a building announcement, not this research paper.